7 studies found for:    "Thrombasthenia"
Show Display Options
Rank Status Study
1 Completed Observational Registry of the Treatment of Glanzmann's Thrombasthenia
Conditions: Congenital Bleeding Disorder;   Glanzmann's Disease
Intervention: Drug: activated recombinant human factor VII
2 Enrolling by invitation A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan
Conditions: Congenital Bleeding Disorder;   Glanzmann's Disease
Intervention: Drug: eptacog alfa (activated)
3 Suspended Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: Thalassemia;   Sickle Cell Disease;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic-granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Schwachman-Diamond Syndrome;   Diamond-Blackfan Anemia;   Fanconi Anemia;   Dyskeratosis-congenita;   Chediak-Higashi Syndrome;   Severe Aplastic Anemia
Intervention: Drug: Alefacept
4 Completed Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
Conditions: Congenital Bleeding Disorder;   Congenital FVII Deficiency;   Glanzmann's Disease;   Acquired Bleeding Disorder;   Acquired Haemophilia
Intervention: Drug: activated recombinant human factor VII
5 Recruiting Abatacept Reduced Intensity for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman Diamond Syndrome;   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Chediak Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia;   Hemophagocytic Lymphohistiocytosis
Interventions: Drug: 4 doses of abatacept;   Drug: 6 doses of abatacept
6 Recruiting The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
Condition: Glanzmann Thrombasthenia
Intervention:
7 Completed Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
Conditions: Acquired Bleeding Disorder;   Acquired Haemophilia;   Congenital Bleeding Disorder;   Congenital FVII Deficiency;   Glanzmann's Disease;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors;   Healthy
Intervention: Drug: activated recombinant human factor VII

Indicates status has not been verified in more than two years